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Argentine sublineage), poorly cross-neutralizes some Florida
sublineage Clade (Fc) 2 strains which have one amino acid sub-
stitution at position 144 in antigenic site A of the hemagglutinin,
e.g. A/equine/Carlow/2011 (CL11). Because of that, Japanese vac-
cine manufacturers are updating their vaccines by replacing LP93
with a Fc2 strain, i.e. A/equine/Yokohama/aq13/2011 (Y10, Fc2).
We compared the efﬁcacy of the updated vaccine with that of the
vaccine containing LP93 in horses experimentally challenged
with CL11. Ten naïve horses were randomly separated into 2
groups, Y10 and LP93 groups. The horses in each group were
vaccinated twice one month apart by intramuscular injection of
the monovalent vaccine containing inactivated Y10 or LP93 strain.
Two horses in each groupwere experimentally infectedwith 109.4
50% egg infectious dose/horse of CL11, twoweeks after the second
vaccination. The remaining three horses in each group were
experimentally infected four weeks after second vaccination. The
rectal temperatures were recorded, and nasopharyngeal swabs
were collected daily for 14 days after the challenge. The geometric
mean (GM) of the virus neutralization (VN) titer against CL11 of
the Y10 and LP93 groups on the day of challenge, i.e. Day 0, was
48.5 and 10.6, respectively. Contrarily, the GM haemagglutination
inhibition (HI) titers against CL11 of the Y10 and LP93 groups on
Day 0 were similar (i.e. 27.9 or 24.3, respectively). The mean rectal
temperatures of the LP93 group were signiﬁcantly higher than
those of the Y10 group on Days 2 to 7, except for Day 4 after
challenge. The mean duration (3.0 days) of pyrexia (38.5C) of
the LP93 group was signiﬁcantly longer than that of Y10 group
(0.4 days). The virus was isolated from the swabs collected from
all the horses, except for two horses in the Y10 group. No signif-
icant difference in the duration of virus shedding was observed
between the groups. This study demonstrated the superior efﬁ-
cacy of the Y10 vaccine in terms of mitigation of pyrexia
compared to that of the LP93 vaccine. The GM HI titres against
CL11 were similar for the two groups on Day 0 and the difference
in vaccine efﬁcacy was probably due to the approx. 4.6-fold dif-
ference in GM VN titres between the groups. Thus this study
suggests that in horses, VN tests are more likely than HI tests to
identify antigenic differences in inﬂuenza viruses which could
affect vaccine efﬁcacy.
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Every year, several Equine Inﬂuenza (EI) epizooties are reported
worldwide, which may have important welfare and/or economic
consequences. EI vaccination is one of the most efﬁcient methods
of prevention. However, not all horses develop protective im-
munity after EI immunisation, increasing the risk of infection,
virus shedding and the spread of the disease. Objectives: This
study aimed to better understand the poor response to primary EI
vaccination. Study design: The EI antibody response was
measured in 117 thoroughbred foals set in 3 different stud farms
(SF#1 to SF#3) during primary EI immunisation with a commer-
cial recombinant canarypox-based EI vaccine, following themanufacturer recommendations. The age at ﬁrst vaccination was
159.3±27.6 days (17 to 37weeks). Serawere tested by single radial
haemolysis (SRH) against the A/equine/Jouars/4/2006 EIV strain
(H3N8; Florida Clade 2) at the time of the ﬁrst vaccination (V1), 2
weeks and 3 months after the second immunisation (V2), 2 days
and 3 months after the third immunisation (V3). Results: The
short (V2+2 weeks) and mid-term (V2+3 months and V3+3
months) SRH antibody levels were statistically different between
the stud farms (p-value¼0.031, 0.027 and 0.0003, respectively). At
both time points, SRH antibody titres were positively correlated to
the age of foals at V1 (p-value¼0.003 and 0.0038, respectively).
Presence of maternal derived antibody (MDA) at V1 had no
impact on short-term antibody titres (V2+2 weeks; p-value¼0.27)
but was negatively correlated with titres after V3 (p-val-
ue¼0.0056). Given that SF#1 antibody response was below clin-
ical protective levels (i.e. 85 mm2) at all time points studied, the
annual boost immunization (V4) was brought forward by 5.4±1
months to restore protective antibody levels. The average age at
ﬁrst immunisationwas delayed by 48.7 days the following year in
SF#1, which signiﬁcantly increased SRH antibody titres (p-val-
ue¼9.9e-07). Conclusion: Independently of the presence of MDA,
the age of foals at ﬁrst immunisationwith the canarypox-based IE
vaccine plays an important role in the establishment of adequate
antibody levels. This study also highlights the beneﬁt provided by
serological surveillance in order to evaluate the protection level of
a speciﬁc population, to identify poor vaccine responder and to
implement corrective management/vaccination measures.
ĂEthical Animal Research: Ethical approval and owner consents
were obtained.
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Current equine inﬂuenza vaccines elicit a strong humoral immune
response against surface glycoproteins, in particular haemag-
glutinin (HA). However, the virus undergoes continuous evolution
by mutation of sequences encoding amino acids, mostly those
present in the exposed head domain of HA, which results in poor
induction of cross-reactive antibodies against non-matching
strains. In contrast, it has been reported that epitopes in the stem
region of HA are highly conserved and can be used to stimulate a
10th IEIDC Abstracts / Journal of Equine Veterinary Science 39 (2016) S72eS77S76broader immune response. This work describes the generation of
two immunogens based on the stem region of HA from the A/
Equine/Argentina/93(H3N8) inﬂuenza strain: a recombinant pro-
tein expressed in prokaryotic cells (DHAp), and a DNA vaccine
(DHAe). A DNA fragment encoding DHAp was cloned into the
pET22b vector, and the recombinant protein was puriﬁed from in-
clusion bodies. The DHAe coding sequence was cloned into
eukaryotic vectors that were transfected in HEK 293T cells. The
expression of proteins was determined by Western blot assay. The
immunogenicity of both vaccine candidates was studied using
different combination of antigens in mice. Immunizations were
done two times with a three-week interval. The DNA vaccine was
given intramuscularly and the recombinant protein was given
intraperitoneally in incomplete Freund’s adjuvant (Sigma). A group
ofﬁvemice received two immunizationswith 50ugofDNAvaccine;
a second group received two immunizations with 10 ug of recom-
binant protein; a third groupwas primedwith 50 mg of DNAvaccine
and boostedwith 10 ug of recombinant protein; a fourth groupwas
primedwith10ugofproteinandboostedwith50mgofDNAvaccine;
and a ﬁfth group received only PBS. We found that immunization
with twodosesof recombinantproteinwasmore immunogenic that
vaccination with DNA only or combination of DNA and protein. In
order to analyze cross-reactivity of the immune sera, ELISA plates
were coatedwith4HAunits of inﬂuenzastrainsbelonging togroups
1 (H1N1) and 2 (H3N2). Plates coated with recombinant protein
were used as a positive control. Higher antibody titers against vi-
ruses belonging to the same phylogenetic group were observed
when mice were immunized with recombinant protein. However
antibody titers were broader and reacted against viruses belonging
to different phylogenetic groups when mice were immunized with
DNA. Conclusions: Recombinant proteins were expressed correctly
in prokaryotic and eukaryotic systems. Homologous antibody titers
were higher in animals immunized with recombinant proteins,
while DNA immunization induced a heterotypic immune response.
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Equine inﬂuenza (EI) is highly contagious acute respiratory dis-
ease of equines caused by Inﬂuenza A virus belong to the family
Orthomyxoviridae. Like other inﬂuenza viruses, equine inﬂuenza
virus (EIV) show periodic antigenic drift that leads to vaccines
strains becoming redundant. This necessitates regular harmoni-
zation of vaccines and strain substitution. The studies in large
animals for potency testing is difﬁcult and suitable small animal
model is required for testing the protective efﬁcacy of the novel or
updated EI vaccine candidates prior to ﬁnal testing in equines. The
present investigation focuses on use of BALB/c mice for studying
the protective efﬁcacy of inactivated indigenous H3N8 vaccine
subsequent to challenge with EIV. BALB/c mice immunized with
inactivated EI vaccine were challenged through intranasal instil-
lation of EIV @ 2x106.24 EID50 in 20ul volume. Mice were moni-
tored for humoral immune response kinetics (HAI), clinical
examination, virus isolation, qRT-PCR, histopathology and
immunohistochemistry (IHC). Immunized mice showed HAI titre
of 138.67±25.69 after two boosters. Clinically unvaccinated mice
suffered severe respiratory disease and showed respiratorydistress, forced expiration, rufﬂed coat, reduced activity and
crouching at corners at 2-7 days post challenge (dpc) with
6.34±0.21 % weight reduction at 5 dpc, whereas vaccinated mice
showed minimal signs at 2-4 dpc with 3.69±0.13% weight
reduction at 2 dpc. Hematology showed mild leucopenia with
lymphopenia at 7 dpc and lymphocytosis at 3 dpc in unvaccinated
and vaccinated mice, respectively. Gross lesions in unvaccinated
mice after challenge were congestion of nasal mucosa, grayish
mucinous exudate in trachea, severe consolidation (3-4mm 2-3
mm) of lung parenchyma with congestion and gray discoloration
at 2-5 dpc. In comparison, vaccinated mice showed only
congestion of lung parenchyma without consolidation at similar
intervals. Main histopathological changes viz. rhinitis, tracheitis,
necrosis of bronchi and bronchiolar epithelium, peribronchitis
and perivascular cufﬁng of neutrophils and lymphocytes, diffuse
interstitial pneumonia were restricted to respiratory tract in un-
vaccinated mice at 3-5 dpc. Vaccinated mice developed mild
respiratory lesions which resolved rapidly (2-3dpc). Gross and
histopathological scoring revealed that vaccinated mice devel-
oped fewer lesions than unvaccinated mice upon challenge. Un-
vaccinated and vaccinated mice showed similar EIV antigen
distributions in nasal turbinate, trachea and lung, but intensity
and duration of positivity was less in vaccinated mice. Virus
isolation from nasal washings and lung tissues showed less virus
shedding (1.25 log10 EID50/ml) and early clearance (1 dpc) in
vaccinated than unvaccinated mice (5.25 log10 EID50/ml at 1 dpc
and persisted up to 5 dpc). Further, qRT-PCR showed unvacci-
nated mice shed signiﬁcantly more virus in nasal washings and
lungs up to 5 dpc as compared to vaccinated mice which shed
very less virus up to 3 dpc. Thus, it can be concluded from the
present investigations that BALB/c mice is a potential small ani-
mal model for testing EIV vaccine candidates prior to testing in
ﬁnal host. Findings of the study will be discussed in detail during
the presentation.
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Equine inﬂuenza virus (EIV) belongs to the Orthomyxoviridae
family and is responsible for the severe acute respiratory disease
of equine inﬂuenza (EI) in the horse population. Two genotypes of
EIV have been isolated, H7N7 (considered extinct) and, H3N8 that
has diverged into American and the European lineages. The
American lineage further evolves into the Kentucky, South
American, and Florida clade 1 and 2. Currenly, Florida Clade 1 and
2 are the most prevalent genotypes worldwide. In China, four
main EI epizootic events (1970, 1989, 1994 and 2007-2008)
occurred. The analyses showed that all EIV were related and
clustered in a single branch belonged to Florida Clade 2. The
strains present in the vaccine are SouthAfrica/1/2003 and Ibaraki/
1/2007 and, although vaccination is currently implemented in
China, sporadic even of EI were detected during the last years. The
aim of this work is analyze the EIV detected during 2011, 2013 and
2015 in China based on phylogenetic and structural analyses of
hemagglutinin protein.The Data set were constructed by BLAST
analyses with Huabei/1/2007 strain to deﬁned sequences to
compared. One hundred and two HA sequences available in
GenBank were used. The phylogenetic analyses was carried out in
